Pfizer's anti-GDF-15 antibody ponsegromab was able to achieve weight gain in cancer patients with cachexia – a life-threatening metabolic syndrome caused by the underlying disease with no ...

Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating yesterday. David Risinger has ...

Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating on October 21. David Risinger ...

CEO Albert Bourla, who is under attack from activist investor Starboard Value, got a much-needed victory on Tuesday as Pfizer ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year A boost from COVID-19 treatment sales helped bush Pfizer to a ...

Q3 2024 Earnings Conference Call October 29, 2024 10:00 AM ETCompany ParticipantsFrancesca DeMartino - Chief Investor ...

Pfizer offers a generous 5.73% dividend yield. The stock is trading at an attractive forward P/E of 9.5x 2026 earnings. The company has multiple potential growth drivers in its pipeline. Pfizer's ...

Pfizer won the gratitude of governments and patients alike with the vaccine and its antiviral treatment, Paxlovid. CNN named Bourla CEO of the year in 2021, beating out Alphabet’s Sundar Pichai ...

Pfizer is making strides in the rapidly growing weight management market. The company is committed to developing a franchise around obesity and cachexia treatments. This focus aligns with the ...

Pfizer stock (NYSE: PFE) currently trades at $29 per share, 45% below its peak level of $54 seen in December 2021. In contrast, Merck stock is up 54% over this period. PFE stock was trading at $47 ...

The third-quarter 2024 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer’s R&D pipeline can be found at www.pfizer.com.

Albert Bourla, who four years ago led Pfizer through its scientific and financial triumph during the covid-19 pandemic, is suddenly facing a new challenge from a large shareholder frustrated over ...